Talc Pleurodesis

on

 Talc Pleurodesis

1. Cause / Purpose of Talc Pleurodesis

Talc pleurodesis is not a disease, but a therapeutic medical procedure used to obliterate the pleural space to prevent recurrent pleural effusions or pneumothoraces. It involves the instillation of sterile talc powder into the pleural space to induce inflammation and fibrosis, resulting in adhesion of the visceral and parietal pleura.

Common indications:

  • Malignant pleural effusion (most common)
  • Recurrent pneumothorax
  • Chylothorax
  • Refractory benign pleural effusions

2. Etiology

Since talc pleurodesis is a deliberately induced condition, its "etiology" refers to why and how it is performed, rather than a natural cause. The etiological rationale is:

  • Mechanical prevention of pleural fluid or air reaccumulation.
  • Symptomatic relief (e.g., dyspnea).
  • Improved quality of life in palliative care settings.

Talc is the agent of choice due to:

  • High efficacy
  • Low cost
  • Broad availability
  • Minimal systemic absorption

3. Pathophysiology

Talc pleurodesis causes intentional pleural inflammation and fibrosis:

  1. Talc particles (preferably large-particle, asbestos-free, medical-grade) are insufflated or instilled into the pleural space.
  2. These particles cause local irritation, leading to:
    • Activation of mesothelial cells
    • Release of proinflammatory cytokines (e.g., IL-8, TNF-α, TGF-β)
    • Neutrophil and macrophage infiltration
  3. This cascade results in exudative pleuritis and fibrous adhesion between the parietal and visceral pleura.
  4. Permanent pleural symphysis obliterates the pleural space, thereby preventing further fluid or air accumulation.

The degree of inflammation depends on:

  • Talc particle size (smaller particles increase systemic dissemination and side effects)
  • Dose
  • Patient’s immune status

4. Epidemiology

Since talc pleurodesis is procedural:

  • Its “epidemiology” depends on the underlying condition (e.g., pleural malignancy).
  • Used commonly in oncology and pulmonology.

Malignant pleural effusion (MPE):

  • Occurs in ~15% of all cancer patients.
  • Common in lung cancer, breast cancer, ovarian cancer, mesothelioma, and lymphoma.
  • Talc pleurodesis is one of the most frequently used interventions in the palliative care of MPE.

Pneumothorax:

  • Spontaneous pneumothorax recurrence rates are ~30-50%.
  • Talc pleurodesis is used especially in patients not fit for surgery or with recurrence.

5. Clinical Presentation

Since talc pleurodesis is a treatment, the clinical “presentation” refers to post-procedural symptoms or complications:

Expected post-procedural symptoms:

  • Chest pain (common, due to inflammation)
  • Fever
  • Dyspnea (transient, typically improves after fluid resolution)

Complications:

  • Acute respiratory distress syndrome (ARDS) (rare; more likely with small-particle talc)
  • Empyema
  • Fever of unknown origin
  • Hypoxemia
  • Pneumonitis (especially with talc of non-uniform particle size)
  • Acute pain requiring opioids

6. Imaging Features

Chest X-ray (CXR):

  • Immediate post-pleurodesis: pleural thickening, homogeneous opacity, residual fluid.
  • Later stages: calcified pleura (in some cases).

CT Findings:

  • High attenuation pleural lining (due to talc deposition; >80 HU)
  • Diffuse pleural thickening with increased enhancement
  • Pleural nodularity (must differentiate from malignant pleural disease)
  • Persistent talc may mimic pleural metastasis—clinical history is essential.

PET-CT:

  • Talc can cause increased FDG uptake, mimicking malignancy.
  • Uptake may persist for months or years, especially in areas of inflammation.

Radiological Pearls:

·         Always correlate with a clinical history of pleurodesis.

·         Distinguish from mesothelioma, empyema, or recurrent malignancy.

7. Treatment Strategy

Talc pleurodesis is both diagnostic and therapeutic.

Talc can be administered via:

  • Thoracostomy (tube thoracostomy) with slurry
  • Thoracoscopy (VATS or medical thoracoscopy) with poudrage (spray insufflation)

Key Steps:

  1. Drain the pleural fluid completely.
  2. Ensure full lung expansion.
  3. Instill sterile talc slurry via chest tube OR insufflate talc powder under thoracoscopic guidance.
  4. Clap chest tube for 1–2 hours to facilitate contact.
  5. Unclamp and monitor drainage.

Contraindications:

  • Trapped lung (unexpandable lung)
  • Active infection (empyema)
  • Severe coagulopathy
  • Allergy to talc (rare)

8. Prognosis and Efficacy

Success rate:

  • Varies from 70–90%, higher when performed thoracoscopically.
  • Talc poudrage (via thoracoscopy) may have better outcomes than slurry.

Factors affecting outcome:

  • Lung expansion capacity
  • Presence of malignancy
  • Inflammatory response

Long-term outlook:

  • Permanent pleural adhesion in most patients.
  • Symptom relief (dyspnea) is the main goal.
  • In malignant effusion, part of palliative care, not curative.

Complications and Prognosis:

  • Serious complications (e.g., ARDS) are rare with large-particle talc.
  • Persistent pleural thickening may limit future thoracic procedures.
  • In terminal cancer, it improves quality of life but does not affect survival. 

Chest X-ray Report (Post-Pleurodesis)

Indication: Follow-up imaging post-pleurodesis for malignant pleural effusion.

Findings:
There is evidence of pleural thickening in the right hemithorax, consistent with post-pleurodesis changes. No pneumothorax is seen. The lung appears fully expanded. No significant pleural effusion is currently evident. No acute osseous abnormality. The heart and mediastinum are within normal limits.

Impression:
Stable post-talc pleurodesis changes. No evidence of recurrent effusion or pneumothorax.


Case study: A 69-Year-Old Male with Right Flank Pain
Talc Pleurodesis

History and Imaging Findings

  1. A 69-year-old male presented with complaints of right flank pain.

  2. No respiratory symptoms were reported.

  3. The patient had a history of recurrent left-sided lung collapse and had undergone thoracic surgery on the left side several years prior.

  4. Non-contrast-enhanced abdominal CT was performed, capturing both axial and reformatted sagittal views of the lower thorax. Imaging was reviewed in both soft tissue (upper panels) and lung window settings (lower panels).

  5. No radiologic evidence of urolithiasis was identified.

Quiz

  1. What is the most significant finding on the CT scan?
    (1) Nodular pleural thickening with calcifications
    (2) Left-sided rib fractures
    (3) Right pleural effusion
    (4) Aortic dissection

  2. Which of the following are included in the differential diagnosis of nodular pleural thickening?
    A. Primary pleural malignancy
    B. Metastatic disease
    C. Talc pleurodesis
    D. A, B, and C
    E. None of the above

  3. What are the typical indications for talc pleurodesis?
    A. Recurrent pneumothorax
    B. Recurrent pleural effusion
    C. Both A and B
    D. Neither A nor B

  4. Talc pleurodesis functions by inducing adhesion between the parietal pleura and the chest wall.
    (1) True
    (2) False
    Explanation: Talc pleurodesis works by promoting adhesion between the parietal and visceral pleura.

  5. Talc deposits demonstrate FDG avidity on F-18 FDG PET/CT.
    (1) True
    (2) False
    Explanation: Intense FDG uptake due to granulomatous inflammatory response can persist for decades.

Findings and Diagnosis

Findings
Non-contrast-enhanced CT reveals irregular, hyperdense soft tissue thickening along the multifocal surfaces of the left pleura, with subtle calcifications (red arrows). These findings are consistent with prior talc pleurodesis.

Differential Diagnosis

  • Mesothelioma

  • Pleural metastasis

  • Talc pleurodesis

  • Granulomatous infection

Final Diagnosis:
Talc pleurodesis

Discussion

Talc Pleurodesis

Pathophysiology and Epidemiology
Chemical pleurodesis is a therapeutic procedure performed to prevent recurrent pneumothorax or pleural effusion.
Instillation of talc between the pleural surfaces induces intense intrapleural inflammation and subsequent fibrosis.
This fibrotic reaction leads to adhesion between the visceral and parietal pleura.
The procedure has a reported success rate exceeding 90%.

Clinical Presentation
Patients are generally asymptomatic.
Post-procedural complications may include fever and gastrointestinal symptoms shortly after instillation.

Imaging Characteristics

  • CT: Nodular or linear pleural thickening with variable degrees of calcification. The findings are expected to remain stable over serial imaging.

  • F-18 FDG PET/CT: FDG avidity may be observed in areas of pleural thickening resulting from talc pleurodesis.

Management

  • Long-term adverse effects from talc pleurodesis are minimal.

  • Symptom control is the main focus immediately following the procedure.

Reference

(1)      Baiu I, Yevudza E, Shrager JB. Talc pleurodesis: A medical, medicolegal, and socioeconomic review. Ann Thorac Surg. 2020;109(4):1294-1301.

(2)      Narayanaswamy S, Kamath S, Williams M. CT appearances of talc pleurodesis. Clin Radiol. 2007;62(3):233-237.

(3)      Peek H, van der Bruggen W, Limonard G. Pleural FDG uptake more than a decade after talc pleurodesis. Case Rep Med. 2009;2009:650864.

Comments

Post a Comment